Business News

Medtronic to Acquire Medicrea and its Spinal Surgery Technology

DUBLIN & LYON, France–(BUSINESS WIRE)–Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered …

Read More »

Sanofi and MD Anderson Enter Strategic Collaboration to Accelerate Oncology Research and Development

CAMBRIDGE, Mass. and HOUSTON, July 14, 2020 /PRNewswire/ — Sanofi and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune-therapies, for patients with cancer. The alliance will combine MD Anderson’s clinical trials infrastructure and …

Read More »

Blueprint Medicines Collaborates with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize …

Read More »

Dewpoint Therapeutics and Merck Partner to Evaluate Novel Approach for the Treatment of HIV

BOSTON–(BUSINESS WIRE)–Dewpoint Therapeutics, the biomolecular condensates company, announced today that it has forged an exclusive collaboration agreement with Merck, known as MSD outside the United States and Canada, to apply Dewpoint’s proprietary platform for condensate-based drug discovery to the development of a novel mechanism for the treatment of HIV. Biomolecular condensates are …

Read More »

Sanofi and Kymera Therapeutics Enter Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

CAMBRIDGE, Mass., July 9, 2020 /PRNewswire/ — Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage …

Read More »

ProteinQure and AstraZeneca Collaborate to Design Novel Peptide Therapeutics

TORONTO–(BUSINESS WIRE)–ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics. Peptide therapeutics have unique properties that make them highly effective …

Read More »

Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Takeda Pharmaceutical Company Limited (Takeda) for access to proprietary phage display libraries for the discovery, validation and optimization of …

Read More »

Xencor and Atreca Partner to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on …

Read More »

Merck and Foghorn Collaborate to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control™ product platform …

Read More »

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

CARLSBAD, Calif., July 8, 2020 /PRNewswire/ — Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test …

Read More »